GNMX Aevi Genomic Medicine, Inc.

1.62
0  -5%
Previous Close 1.70
Open 1.73
Price To book 1.80
Market Cap 60.12M
Shares 37,109,000
Volume 1,223,944
Short Ratio 3.30
Av. Daily Volume 628,388

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data due 2H 2017.
AEVI-002 (Anti-LIGHT mAb)
Pediatric onset Crohn's disease
Phase 1/2 commencement of enrollment announced January 31, 2017.
AEVI-001 (NFC-1)
22q11.2 Deletion Syndrome
Phase 2/3 data released March 20, 2017 - primary endpoint not met.
NFC-1 - SAGA
mGluR mutation positive ADHD

Latest News

  1. Today's Research Reports on Stocks to Watch: Pulmatrix and Aevi Genomic Medicine
  2. Aevi Genomic Medicine downgraded by Jefferies
  3. Why Aevi Genomic Medicine Got Crushed Today
  4. AEVI GENOMIC MEDICINE, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  5. Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
  6. Aevi Genomic Medicine to Present at the Oppenheimer 27th Annual Healthcare Conference
  7. AEVI GENOMIC MEDICINE, INC. Financials
  8. AEVI GENOMIC MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
  9. Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
  10. AEVI GENOMIC MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure
  11. Aevi Genomic Medicine to Present at the Cowen and Company 37th Annual Health Care Conference
  12. Aevi Genomic Medicine Announces Expansion of its Collaboration with The Children's Hospital of Philadelphia
  13. Aevi Genomic Medicine Announces 2017 Investor Day
  14. Aevi Genomic Medicine to Present at the Leerink Partners 6th Annual Global Healthcare Conference
  15. ($$) Clinical Development News, Jan. 30-Feb. 3
  16. Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome
  17. Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents
  18. Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents
  19. Aevi Genomic Medicine, Inc. :GNMX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 23, 2016
  20. AEVI GENOMIC MEDICINE, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Othe